Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
LONDON and SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
点赞
举报
登录后可参与评论
![empty](https://c1.itigergrowtha.com/community/assets/media/empty-default.06ba11e0.png)
暂无评论